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Non–antigen-specific stimulatory cancer immunotherapies are commonly complicated by
off-target effects. Antigen-specific immunotherapy, combining viral tumor antigen or
personalized neoepitopes with immune targeting, offers a solution. However, the lack of
flexible systems targeting tumor antigens to cross-presenting dendritic cells (DCs) limits
clinical development. Although antigen–anti-Clec9A mAb conjugates target cross-
presenting DCs, adjuvant must be codelivered for cytotoxic T lymphocyte (CTL) induction.
We functionalized tailored nanoemulsions encapsulating tumor antigens to target Clec9A
(Clec9A-TNE). Clec9A-TNE encapsulating OVA antigen targeted and activated cross-
presenting DCs without additional adjuvant, promoting antigen-specific CD4+ and CD8+ T
cell proliferation and CTL and antibody responses. OVA-Clec9A-TNE–induced DC
activation required CD4 and CD8 epitopes, CD40, and IFN-a. Clec9A-TNE encapsulating
HPV E6/E7 significantly suppressed HPV-associated tumor growth, while E6/E7–CpG did
not. Clec9A-TNE loaded with pooled B16-F10 melanoma neoepitopes induced epitope-
specific CD4+ and CD8+ T cell responses, permitting selection of immunogenic
neoepitopes. Clec9A-TNE encapsulating 6 neoepitopes significantly suppressed B16-F10
melanoma growth in a CD4+ T cell–dependent manner. Thus, cross-presenting DCs
targeted with antigen–Clec9A-TNE stimulate therapeutically effective tumor-specific
immunity, dependent on T cell help.
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Introduction
The clinical success of monoclonal antibody therapy targeting 
immune checkpoint modulators has stimulated much enthusiasm 
for anticancer immunotherapy. Although promising, checkpoint 
inhibitors provide clinical benefit to a limited number of patients, 
and response is heterogeneous, mainly because of different lev-
els of immunogenicity among cancer subtypes. Moreover, treat-
ment with these drugs is also often associated with the induction 
of adverse autoimmune reactions due to the lack of specificity of 
therapeutic effects. There is thus a clinical need to tailor antitumor 
immune responses more precisely toward the specific and often 
unique antigens of individual tumors. This possibility is now made 
practically feasible by advanced genomic sequencing, which 
identifies the mutational landscape of each individual tumor and 
specific neoantigens targeted by the host immune system, when 
released from regulatory checkpoints.
Cancer vaccines are designed to generate tumor-specific T lym-
phocytes and therefore may complement the capacity of checkpoint 
inhibitors to reinvigorate tumor-specific T cells (1–5). However, can-
cer vaccination is challenging (1). Recently, small trials of 2 candi-
date vaccine approaches to enhance immunity toward tumor neo-
epitopes — long polypeptides with adjuvant and stimulatory tumor 
RNA lipoplexes — demonstrated safety, feasibility, and immuno-
genicity of neoepitope vaccination (6, 7). Furthermore, vaccina-
tion with E7 peptides and adjuvant was immunogenic and reduced 
progression of human papillomavirus–driven (HPV-driven) vulval 
carcinoma (8–10). These approaches deliver vaccine antigens with 
adjuvant to dendritic cells (DCs), inducing antigen-specific cyto-
toxic T lymphocytes (CTLs), type I IFN, and antitumor immunity 
(7). However, such strategies rely on passive targeting of DCs of all 
subtypes in lymphoid tissues, some of which induce predominantly 
regulatory responses. Furthermore, because neoepitopes predicted 
to bind MHC molecules may stimulate regulatory T cell responses, 
strategies are needed to enrich for the most immunogenic sequenc-
es to induce both CD4+ and CD8+ tumor-specific responses.
Cross-presenting DCs are BATf3+CD103+CD8+ in mice and 
CD141+ in humans (11, 12). They infiltrate tumors and take up anti-
gens released by dying tumor cells and, when signaled by type I 
IFN, are able to induce strong and specific CD4+ and CD8+ T cell 
responses (13, 14). In the absence of BATf3, checkpoint inhibitors 
and vaccine strategies suppress tumors poorly (15, 16). CTL induc-
tion requires the activation of CD8 epitope–loaded DCs with either 
adjuvant or CD40 signaling by cognate CD40L+CD4+ helper T 
cells (17, 18). Flexible and immunogenic systems targeting tumor 
antigens to cross-presenting DCs in vivo thus represent the key to 
induction of CD8+ and cognate CD4+ tumor-specific responses in 
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could be achieved, the immunogenicity of TNE-encapsulated anti-
gen was not explored. Here we show unexpectedly, given the lack 
of DC activation by anti-Clec9A–antigen conjugates, that in the 
absence of adjuvant, cross-presenting DCs targeted with antigen–
Clec9A-TNE stimulate DC activation, antigen-specific CTLs, and 
highly effective tumor-specific immunity, dependent on the pres-
ence of CD4 helper epitopes and CD40 signaling.
Results
To target antigen to Clec9A+ DCs in vivo, we first encapsulated 
OVA antigen into Clec9A-TNE (OVA-Clec9A-TNE) using a dou-
ble emulsion method. OVA-Clec9A-TNE had a similar size dis-
tribution, as measured by dynamic light scattering, when diluted 
in water or isotonic PBS (Supplemental Figure 1A; supplemental 
material available online with this article; https://doi.org/10.1172/
JCI96791DS1), and maintained stability when stored at 4°C for up 
to 256 days (Supplemental Figure 1B). As stability of nanocarriers 
in physiological conditions is required for effective cellular target-
ing, the data suggest that OVA-Clec9A-TNE are stable in physi-
ological environments and suitable for i.v. injection. To assess in 
vivo biodistribution, we labeled Clec9A-TNE and the nontargeting 
isotype-TNE with the fluorescent lipophilic dye DiR, and injected 
each preparation i.v. via tail vein into BALB/c mice. Live mice were 
imaged 24 hours (Figure 1A) and 7 days (Figure 1, B and C) after 
injection using in vivo imaging. Clec9A-TNE and isotype-TNE 
but not free dye control accumulated in liver and spleen 24 hours 
after injection (Figure 1A). At 7 days, Clec9A-TNE accumulated in 
spleen (Figure 1B), whereas isotype-TNE accumulated in the liver 
(Figure 1C). Clec9A-TNE but not isotype-TNE were taken up by 
splenic CD8+ DCs and pDCs. Both TNEs were taken up to a sim-
ilar, small extent by CD8– DCs (Figure 1D). Rapid antigen degra-
dation in lysosomal compartments reduces cross-presentation 
but supports MHC class II–mediated presentation, while antigens 
delivered to early endosomes are cross-presented efficiently (32, 
33). To determine the intracellular localization of Clec9A-TNE, 
we sorted splenic CD11c+ DCs from naive mice, incubated them 
with fluorescently labeled Clec9A-TNE or isotype-TNE for 3 
hours, then stained early endosomes and lysosomes using the cell 
compartment markers EEA1 and LAMP1, respectively. Internal-
ized Clec9A-TNE colocalized with EEA1 and LAMP1, while iso-
type-TNE colocalized with LAMP1 only (Figure 1E). These data 
indicate that, after recognition by the Clec9A receptor, TNEs are 
internalized and reach early endosomes and lysosomes. In con-
trast, isotype-TNE are not efficiently taken up by the cells (Figure 
1E), but the low levels that are internalized reach only lysosomes.
OVA and other antigens conjugated to anti-Clec9A mAb to tar-
get CD8+ DCs have been shown to induce antigen-specific CD4+ 
and CD8+ T cell proliferation and strong antibody responses in mice, 
but not DC activation (19). We tested the capacity of OVA-Clec9A-
TNE to induce proliferation of antigen-specific T cells and their 
CTL activity in the absence of adjuvant. CellTrace Violet–labeled 
(CTV-labeled) CD8+ (OT-I) or CD4+ (OT-II) OVA-specific T cell 
receptor transgenic T cells were adoptively transferred to B6.SJL-Pt-
prca mice, followed by i.v. injection of OVA-Clec9A-TNE, OVA-iso-
type-TNE, empty Clec9A-TNE, or the same quantity of soluble 
OVA as delivered in TNE. Six days after immunization with OVA-
Clec9A-TNE, the proliferative response of transferred antigen-spe-
the clinic. Current approaches to target cross-presenting DCs have 
chemically or molecularly conjugated antigen to mAbs recogniz-
ing specific endocytic receptors (19–22) such as the C-type lectin 
receptor Clec9A, or DNGR, which is expressed by cross-presenting 
DCs and plasmacytoid DCs (pDCs) in mice, and CD141+ (BDCA3+) 
DCs in humans (19, 23, 24). In vivo, Clec9A organizes the process-
ing and cross-presentation of dead cell and viral antigens by MHC 
class I, resulting in CTL induction for viral and tumor immunity 
(19, 24). However, Clec9A-antigen conjugates are challenging to 
manufacture and require additional costimulation or adjuvant to 
elicit antitumor immune responses. In fact, although Clec9A con-
jugates reproducibly induce high titers of specific antibody after a 
single i.v. inoculation without additional adjuvant, CTL induction 
requires systemic coadministration of agonist anti-CD40 and/or 
TLR-agonist adjuvant (22, 24), which may increase the risk of sys-
temic inflammatory adverse effects. An alternative approach used 
a peptide to target Clec9A+ DCs with OVA257–264, but in vivo CTL 
priming also required adjuvant (25).
Here we combined the concepts of systemic nanoparticle deliv-
ery and targeting of antigen to cross-presenting DCs in an alter-
native approach, in which we encapsulated antigen excipient in a 
Clec9A-targeting tailorable nanoemulsion (Clec9A-TNE). Oil-in-
water nanoemulsion systems have an excellent safety profile and 
are widely used as clinical vaccine adjuvants (26–30). We report-
ed previously that intraperitoneally injected Clec9A-TNE, grafted 
with immune-evading polymer PEG and anti-Clec9A mAb using 
a noncovalent click self-assembly, evaded nonspecific phagocyto-
sis and clearance and targeted antigen to CD8+ DCs in mice. OVA 
encapsulated within the TNE oil core induced antigen-specific 
CD8+ T cell responses in vitro (31). Although this platform nano-
carrier technology showed that targeting of cross-presenting DCs 
Figure 1. OVA-Clec9A-TNE targets cross-presenting DCs and promotes 
antigen-specific T cell responses. (A) Images of C57BL/6 mice 1 day after 
i.v. injection of DiR-labeled Clec9A-TNE, isotype-TNE, or free DiR solution 
as indicated. (B and C) Images of C57BL/6 mice 7 days after i.v. injection 
of DiR-labeled Clec9A-TNE (B) or DiR-labeled isotype-TNE (C).  p/s/cm/sr/
μW/cm2, radiant efficiency, total photons per second per square centimeter 
per steradian in the irradiance range (microwatts per square centime-
ter); p, photons; sr, steradian. (D) Binding/uptake of TNE by CD8+ cDCs, 
CD8– cDCs, and pDCs in C57BL/6 mouse spleen 1 day after i.v. injection (n 
= 3). (E) CD11c+ DCs sorted from naive C57BL/6 mice were incubated with 
DiI-labeled Clec9A-TNE or isotype-TNE (red) for 3 hours. Cells were then 
washed and stained with anti-EEA1 or anti-LAMP1 (green) and DAPI (nuclei, 
blue). (F and G) Proliferation of CD8+ OT-I (F) and CD4+ OT-II (G) cells in 
inguinal lymph nodes (LN) and spleen 6 days after i.v. injection of 5 μg of 
soluble OVA, or 200 μl of Clec9A-TNE, OVA-Clec9A-TNE, or OVA-isotype-TNE 
(formulated with 5 μg of OVA). (H) OT-I T cell proliferation in spleens of 
mice 5 days after i.v. injection of OVA-Clec9A-TNE, OVA-isotype-TNE (each 
formulated with 200 ng of OVA), or 1 μg of OVA anti-clec9A^(10B4)-OVA or 
isotype^(GL117)-OVA fusion protein conjugates without or with CpG (n = 4 
from 2 individual experiments). Serum IFN-α level at 2, 4, and 24 hours after 
vaccination was measured by ELISA. (I) Percent in vivo OVA-specific killing 
5 days after i.v. injection with OVA-Clec9A-TNE or OVA-isotype-TNE (both 
formulated with 5 μg of OVA), Clec9A-TNE, or 5 μg soluble OVA (n = 10–14 
from 3 individual experiments). (J) C57BL/6 mice were injected i.v. with 5 μg 
of Clec9A-OVA, OVA-Clec9A-TNE, isotype-OVA, or OVA-isotype-TNE without 
additional adjuvant. Serum anti-OVA Ig titer was quantified 1, 2, and 3 
weeks later by ELISA (n = 10 from 2 separate experiments). *P < 0.05; **P < 
0.01; ***P < 0.001; ****P < 0.0001 by Tukey’s multiple-comparisons test.
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ic SIINFEKL-pulsed splenic target cells labeled with 5 μM of CTV 
(CTVhi) and unpulsed syngeneic splenocytes labeled with 0.5 μM of 
CTV (CTVlo). Twenty hours later, residual SIINFEKL-specific target 
cells were enumerated relative to unpulsed splenocytes in recipient 
mice. After immunization with OVA-Clec9A-TNE, approximate-
ly 80% of SIINFEKL-specific targets were killed (Figure 1I). In 
contrast, no OVA-specific killing was induced in mice immunized 
with nontargeting OVA-isotype-TNE or soluble OVA. Given that 
Clec9A-TNE traffic to both endosomes and lysosomes and induce 
CD4+ T cell proliferation in vivo, we compared anti-OVA antibody 
induction by OVA-Clec9A-TNE, OVA-isotype-TNE, and OVA con-
jugated to anti-Clec9A or isotype mAb (10B4-OVA, GL117-OVA). 
Each group received an equivalent i.v. dose of 5 μg of OVA. The 
anti-OVA response induced by Clec9A-OVA conjugate was signifi-
cantly greater than the response to isotype-OVA, and the response 
to OVA-Clec9A-TNE was significantly greater than the response to 
OVA-isotype-TNE and Clec9A-OVA conjugate (Figure 1J).
cific CD4+ and CD8+ T cells, as determined by dilution in CTV 
fluorescence intensity, was significantly increased relative to mice 
immunized with OVA-isotype-TNE or empty Clec9A-TNE or mice 
injected with the same amount of soluble OVA (Figure 1, F and G). 
We compared OVA-Clec9A-TNE in the same assay as anti-Clec9A–
OVA and isotype-OVA fusion protein conjugates without or with 
CpG adjuvant. Only preparations targeting OVA to Clec9A induced 
OVA-specific CD8+ T cell proliferation. The CD8+ T cell response 
was significantly greater in response to OVA-Clec9A-TNE than to 
Clec9A-OVA conjugate. Clec9A-OVA plus CpG stimulated signifi-
cantly higher proliferation. Despite this, only OVA-Clec9A-TNE 
stimulated production of systemic IFN-α, detectable in serum with-
in 24 hours (Figure 1H). OVA257–264 (SIINFEKL) is the dominant OVA 
CTL epitope in C57BL/6 mice and is commonly used to investigate 
CTL-mediated killing of target cells. Five days after immunization 
with OVA-Clec9A-TNE, OVA-isotype-TNE, empty Clec9A-TNE, or 
soluble OVA, recipients were injected with an equal mix of syngene-
Figure 2. OVA delivered by Clec9A-TNE promotes MyD88-dependent DC activation and IFN-α production. (A) C57BL/6 mice were injected i.v. with OVA-Cle-
c9A-TNE, OVA-isotype-TNE, Clec9A-TNE, or isotype-TNE. Six hours later, surface expression of CD86, CD80, and CD40 by CD8+ DCs, CD8– DCs, and pDCs was 
analyzed by flow cytometry (n = 6 from 2 separate experiments). (B) C57BL/6 or TLR4–/– mice were adoptively transferred with equal numbers of unpulsed 
CFSElo and SIINFEKL-pulsed CFSEhi target cells 6 days after i.v. injection with OVA-Clec9A-TNE or OVA-isotype-TNE. The percentage of SIINFEKL peptide–
specific lysis in spleen is depicted (n = 7–12 from 3 separate experiments). (C and D) C57BL/6, Casp1–/–, IFNAR1–/–, MyD88–/–, or CD40–/– mice were injected i.v. 
with OVA-Clec9A-TNE. Six hours later the expression of CD86 by CD8+ splenic DCs was analyzed by flow cytometry (C) (n = 7 from 2 experiments), and IFN-α 
levels in serum from these mice were measured by ELISA (D). (E) C57BL/6 (WT), CASP1–/–, IFNAR1–/–, MyD88–/–, or CD40–/– mice were adoptively transferred 
with equal numbers of unpulsed CTVlo and SIINFEKL-pulsed CTVhi target cells 5 days after i.v. injection with OVA-Clec9A-TNE (n = 9–10 from 2 experiments). 
Specific killing of target cells is shown. *P < 0.05; **P < 0.01; ***P < 0.001; ****P < 0.0001 by Tukey’s multiple-comparisons test.
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shown previously not to activate DCs after i.v. injection (19, 22), 
suggesting that the TNE delivery system is particularly immu-
nogenic but only when antigen is encapsulated. Furthermore, 
coadministration of adjuvant — anti-CD40 alone or with poly I:C 
— with Clec9A-OVA conjugate was required for induction of CTL 
responses (22, 24). To determine the mechanism of DC activation 
and CTL induction by OVA-Clec9A-TNE, we first hypothesized 
that recombinant OVA, which contained sufficient endotoxin to 
stimulate an NF-κB–GFP reporter cell line (Supplemental Figure 
3), activated the TLR4 pathway through ligation of endosomal TLR 
after Clec9A-mediated nanoparticle uptake and delivery of OVA 
to the endosome (34), thereby promoting DC activation and CTL 
induction. To test this, we constructed OVA-Clec9A-TNE using 
endotoxin-free OVA, and compared CTL induction by OVA-Cle-
c9A-TNE in TLR4–/– and WT littermate control mice. OVA-specific 
CTLs were induced to a similar extent by OVA-Clec9A-TNE with-
out additional adjuvant and Clec9A-OVA conjugate codelivered 
with poly I:C in littermate controls (Figure 2B). Thus OVA-Clec9A-
TNE induced specific CTLs even when OVA was endotoxin-free. 
Moreover, OVA-specific CTLs were not significantly changed 
Given the immunogenicity of OVA antigen delivered to DCs 
when loaded into Clec9A-targeting TNE relative to nontargeting 
isotype-TNE after i.v. injection in the absence of adjuvant, we 
determined whether DCs were activated after OVA-Clec9A-TNE 
administration. OVA-Clec9A-TNE, OVA-isotype-TNE, empty Cle-
c9A-TNE, or isotype-TNE were administered to mice, and 6 hours 
later splenic DC maturation markers were analyzed by FACS. After 
injection of OVA-Clec9A-TNE, we observed a surprising increase 
in CD86, CD80, and CD40 expression by CD8+ DCs, CD8– DCs, 
and pDCs. OVA-isotype-TNE, empty Clec9A-TNE, and iso-
type-TNE controls did not affect expression of these DC matura-
tion markers (Figure 2A and Supplemental Figure 2). Given almost 
exclusive binding of OVA-Clec9A-TNE to CD8+ DCs and pDCs, 
the upregulation of maturation markers by Clec9A– CD8– DCs 
suggested that ligation of Clec9A and delivery of OVA may have 
promoted a systemic cytokine response and secondary DC activa-
tion. Furthermore, the strong adjuvant effect of OVA- Clec9A-TNE 
compared with empty Clec9A-TNE or OVA-isotype-TNE indicat-
ed that OVA antigen could only activate DCs when delivered in a 
Clec9A-targeted system. In contrast, Clec9A-OVA conjugate was 
Figure 3. OVA-Clec9A-TNE–mediated DC activation and IFN-α production require CD4+ and CD8+ T cell epitope presentation and CD40L-CD40 crosstalk. (A) 
C57BL/6 or RAG1–/– mice were injected i.v. with OVA-Clec9A-TNE, SIINFEKL-Clec9A-TNE, OVA323–339-Clec9A-TNE, or SIINFEKL-OVA323–339-Clec9A-TNE. Six hours 
later, surface expression of CD86 by CD8+ DCs was analyzed by flow cytometry (n = 3–8 from 2 separate experiments). (B) C57BL/6 mice were injected i.v. 
with OVA-Clec9A-TNE, SIINFEKL-Clec9A-TNE, OVA323–339-Clec9A-TNE, SIINFEKL-OVA323–339-Clec9A-TNE, or OVA-isotype-TNE. Serum was collected 2, 4, and 24 
hours after injection, and IFN-α levels were quantified by ELISA (n = 4). (C) C57BL/6 or CD40–/– mice were injected i.v. with OVA-Clec9A-TNE. Six hours later, 
surface expression of CD40, CD80, and CD86 by CD8+ DCs was analyzed by flow cytometry (n = 4). (D) C57BL/6 or CD40–/– mice were adoptively transferred 
with equal numbers of unpulsed CFSElo and SIINFEKL-pulsed CFSEhi target cells 6 days after i.v. injection with OVA-Clec9A-TNE. The percentage of SIINFEKL 
peptide–specific lysis in spleen is depicted (n = 4). (E) Splenic CD11c+ DCs were purified from C57BL/6 mice, then cultured for 5 hours with OT-I OVA-specific 
CD8+ and OT-II OVA-specific CD4+ T cells, in the presence or absence of OVA-Clec9A-TNE or OVA-isotype-TNE. Histograms depict intracellular IFN-α levels in 
gated DC populations. Splenic CD11c+ DCs were purified from C57BL/6 (WT), CD40–/–, or TLR9–/– mice, then cultured for 24 hours with OT-I OVA-specific CD8+ 
and OT-II OVA-specific CD4+ T cells, in the presence or absence of OVA-Clec9A-TNE or OVA-isotype-TNE. (F) Increase in CD40L expression by OT-II cells in 
the presence of OVA-Clec9A-TNE relative to no TNE control. (G) Increase in IFN-α secretion into cell culture supernatant in the presence of OVA-Clec9A-TNE 
relative to no TNE control. Representative data from 6 mice are shown. *P < 0.05; **P < 0.01; ****P < 0.0001 by Tukey’s multiple-comparisons test.
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when OVA-Clec9A-TNE were delivered to TLR4–/– mice (Figure 
2B), indicating that OVA-Clec9A-TNE promote induction of CTLs 
in a TLR4-independent manner. To determine whether MyD88/
TRIF-mediated, inflammasome-mediated, or type I IFN–mediated 
signaling pathways were involved in OVA-Clec9A-TNE–induced 
DC activation, we screened expression of CD86 by CD8+ cDCs 6 
hours after in vivo delivery of OVA- Clec9A-TNE. CD86 induction 
was impaired in IFNAR–/– and MyD88/Trif–/– but not caspase-1–/– 
(Casp1–/–) mice relative to WT mice (Figure 2C). Consistent with 
the IFN dependence of this DC activation, serum IFN-α increased 
8-fold relative to untreated WT mice within 6 hours after injec-
tion of OVA-Clec9A-TNE (Figure 2D). This rapid burst of IFN-α 
suggests secretion by activated pDCs, as observed in Figure 2A 
(35). OVA-Clec9A-TNE did not induce IFN-α when delivered to 
IFNAR–/– and MyD88/Trif–/– mice, consistent with positive-feed-
back activation of CD8+ DCs and pDCs by type I IFN, or crosstalk 
Figure 4. OVA-Clec9A-TNE target lymphoid organs and PyMT-mChOVA tumor and promote a proinflammatory tumor environment associated with tumor 
control. (A) Organs were harvested from untreated or OVA-Clec9A-TNE–treated PyMT-mChOVA tumor–bearing mice. Images show distribution of DiR- 
labeled OVA-Clec9A-TNE in lung, tumor, and spleen, and colocalization with mCherry-expressing tumor. (B) C57BL/6 mice (n = 6–8) developing tumor after 
orthotopic injection of PyMT-mCherry-OVA were treated with OVA-Clec9A-TNE or OVA-isotype-TNE or left untreated. Mean tumor size is plotted over time 
for each group. (C and D) Percentages of M1-like CD11c+CD206– macrophages, total F4/80+CD11b+ macrophages (C), and CD8+ and CD4+ T cells (D) in tumor 
were analyzed by FACS, 6 days after TNE injection. (E) C57BL/6 mice (n = 7) inoculated with 106 AT3-OVA tumor cells and 10 days later injected i.v. once with 
OVA-TNE or OVA-mAb fusion conjugates with or without 10 μg CpG ODN 1668 CpG adjuvant, as indicated. Survival curves of tumor-bearing mice are shown. 
(F) C57BL/6 mice were injected i.v. with DiR-labeled G-actin–TNE, F-actin–TNE, or Clec9A-TNE (left panel) or 10,000 WH-TNE, 50,000 WH-TNE, 100,000 
WH-TNE, and Clec9A-TNE (right panel); 16 hours later, splenocytes were fixed, and then DiR fluorescence intensity was analyzed, indicating uptake of DiR+ 
TNE by CD8+ cDCs. Representative of 4 mice per group. *P < 0.05; **P < 0.01 by 2-way ANOVA test. Survival analyses used the Mantel-Cox log-rank test.
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between DCs (Figure 2D). These data indicate that delivery of OVA 
promotes MyD88/TRIF-dependent and type I IFN–mediated DC 
activation, when targeted to Clec9A+ DCs in the absence of adju-
vant. Consistent with a requirement of DC activation for the induc-
tion of CTLs, low levels of lytic activity were observed after deliv-
ery of OVA-Clec9A-TNE to recipient mice lacking the capacity 
for inflammasome-mediated, type I IFN–mediated, or MyD88/
TRIF-mediated activation (Figure 2E).
CTL induction requires either the activation of DCs 
presenting a CD8 epitope with adjuvant or costimulatory 
CD40-mediated crosstalk from CD4+ T cells (17, 36). Since we 
had observed delivery of OVA-Clec9A-TNE to early and late 
endosomes in vitro and the induction of both CD4 and CD8 
responses in vivo, we explored whether concomitant delivery 
of CD4 and CD8 epitopes in Clec9A-TNE would be sufficient 
to activate DCs in vivo. We encapsulated synthetic sterile SIIN-
FEKL OVA257–264 CD8 epitope, OVA323–339 CD4 epitope, or both 
epitopes in Clec9A-TNE. Both OVA-Clec9A-TNE and Clec9A- 
TNE encapsulating the CD4 and CD8 epitopes, but neither 
OVA323–339- Clec9A-TNE nor SIINFEKL-Clec9A-TNE, activated 
DCs (Figure 3A). Furthermore, there was no difference in DC 
activation by OVA-Clec9A-TNE, Clec9A-TNE encapsulating 
Figure 5. E6/E7–Clec9A-TNE but not E6/E7–CpG vaccination is immunogenic and controls TC1 tumor growth. (A) C57BL/6 mice (n = 10) developing tumor after 
s.c. injection of TC1 were treated with E6/E7–WH-TNE or E6/E7 with 10 μg CpG or left untreated. Mean tumor size is plotted over time for each group, and indi-
vidual mice are shown. (B) Peripheral blood mononuclear cells were stimulated with HPV16 E7 aa49–57 (RAHYNIVTF) peptide, and IFN-γ production was quan-
tified by ELISPOT. (C) Experimental design as in A; survival curves of tumor-bearing mice are shown. (D) Organs were harvested from untreated, DiR-labeled E6/
E7–WH-TNE–treated, or DiR-labeled E6/E7–isotype-TNE–treated TC1 tumor–bearing mice. Images show distribution of DiR-labeled TNE in lung, liver, spleen, 
inguinal lymph node (ILN), and tumor. *P < 0.05; ***P < 0.001; ****P < 0.0001 by 2-way ANOVA test. Survival analyses used the Mantel-Cox log-rank test.
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induced after delivery of OVA-Clec9A-TNE to CD40–/– mice 
(Figure 3, C and D). When CD11c+ DCs were incubated with 
OVA-specific CD4+ and CD8+ T cells in the presence or absence 
of OVA-Clec9A- TNE, IFN-α was expressed only by pDCs (Fig-
ure 3E). pDCs secrete a burst of IFN-α in response to CpG DNA 
sequences, for which signaling of TLR9 in early endosomes is 
required (37, 38). To test the requirement of TLR9 and CD40L/
CD40 signaling for the activation of DCs and IFN-α secre-
tion, we incubated WT, CD40–/–, or TLR9–/– CD11c+ DCs with 
OVA-specific CD4+ and CD8+ T cells in the presence or absence 
the CD4 and CD8 epitopes, or SIINFEKL-Clec9A-TNE in 
RAG1–/– mice, which lack T cells (Figure 3A). Clec9A-TNE 
encapsulating poly I:C or LPS in the absence of antigen acti-
vated DCs much less effectively (Supplemental Figure 4). CD4 
helper epitopes enhance DC activation though CD154-CD40 
interactions. Furthermore, OVA-Clec9A-TNE and Clec9A- 
TNE encapsulating both CD4 and CD8 epitopes promoted 
secretion by pDCs of high serum levels of IFN-α (Figure 3B). 
Consistent with the requirement for CD154-CD40–mediated 
T cell help, neither DC activation nor OVA-specific CTLs were 
Figure 6. Clec9A-TNE encapsulating 
neoepitopes generate neoepi-
tope-specific CD4+ and CD8+ T cell 
responses, which can be used to 
select immunogenic epitopes. (A) 
Schematic describing selection of 
B16-F10 immunogenic epitopes 
by immunogenicity testing. (B–E)
C57BL/6 mice (n = 3) inoculated 
s.c. with B16-F10 were treated with 
Clec9A-TNE loaded with a pool of 
B16-F10 mutated epitopes. Spleno-
cytes were harvested 15 days after 
treatment and restimulated with 
individual epitopes from the pool. 
Expression of IL-10 (B), IFN-γ (C), and 
CD107a/b (D and E) in T cells was 
quantified by FACS.
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These data indicate that Clec9A-TNE are a self-adjuvanting 
vaccine platform that simultaneously promotes CD4+ and CD8+ T 
cell responses to delivered antigen, which would be ideal for cancer 
immunotherapy. To test this, OVA-Clec9A-TNE or OVA-isotype-
TNE were administered i.v. once to C57BL/6 mice, 14 days after 
orthotopic transplant to the mammary fat pad of PyMT-ChOVA 
breast cancer cells. Six days later, DiR-labeled OVA-Clec9A-TNE 
were detected in spleen, as expected (Figure 4A). In the primary 
tumor and lung metastasis, DiR signal colocalized with mCherry, 
consistent with demonstrated tumor infiltration by CD8+ DCs (39). 
of OVA-Clec9A- TNE. The OVA-Clec9A-TNE promoted increased 
CD40L expression by OVA-specific CD4+ T cells and IFN-α secre-
tion into the supernatant in a CD40- and TLR9-dependent man-
ner (Figure 3, F and G). Taken together, our data indicate that after 
Clec9A-targeted OVA antigen delivery, CD8+ DCs are activated as 
a result of type I IFN release and antigen-specific CD40-CD40L–
mediated CD4+ T cell help, to induce antigen-specific CTLs with-
out additional adjuvant. Activation of IFN-α secretion requires 
CD40 signaling as well as TLR9. The latter is most likely activated 
as the TNEs reach the early endosome (37, 38).
Figure 7. Clec9A-TNE encapsulating immunogenic neoepitopes generate antigen-specific T cell responses and suppress the growth of B16-F10 tumors. 
(A) C57BL/6 mice (n = 7) were inoculated s.c. with B16-F10, then treated with WH-TNE or G-actin–TNE loaded with a pool of B16-F10 mutated epitopes, as 
described in Methods, or left untreated. Mean tumor size is plotted over time for each group. (B) C57BL/6 mice (n = 10) were inoculated s.c. with B16-F10, 
then treated with WH-TNE or G-actin–TNE loaded with a pool of B16-F10 mutated epitopes or left untreated 8 days after tumor inoculation. Survival 
curves of tumor-bearing mice are shown. (C) Peripheral blood mononuclear cells were stimulated with B16 epitopes or endogenous survivin peptide, and 
IFN-γ production was measured by ELISPOT. (D) Tumor growth (± CD4-depleting antibody) in mice inoculated s.c. with B16-F10 and treated with WH-TNE 
loaded with the pool of B16-F10 mutated epitopes or left untreated (n = 7). *P < 0.05; **P < 0.01; ***P < 0.001; ****P < 0.0001 by 2-way ANOVA test. 
Survival analyses used the Mantel-Cox log-rank test.
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with individual neoepitopes, to compare IL-10 (Figure 6, A and B) 
and IFN-γ (Figure 6C) production by CD4+ T cells and expression 
of CD107 by CD8+ and CD4+ T cells (Figure 6, D and E) as a mark-
er of degranulation. Regulatory epitopes were identified as low 
stimulators of IFN-γ and CD107 and high stimulators of IL-10, 
and were discarded. The resultant stimulatory pool, consisting of 
6 neoepitopes (five CD4 neoepitopes, MUT20, MUT25, MUT30, 
MUT36, and MUT44, and one CD8 neoepitope, MUT33, with 
highest immunogenicity), was encapsulated into WH-TNE. Two 
days after s.c. implantation of B16-F10 melanoma, mice were 
immunized with WH or control G-actin TNE encapsulating the 
6-neoepitope pool. WH-neoepitope-TNE but not G-actin–neoepi-
tope–TNE significantly suppressed tumor growth and enhanced 
survival (Figure 7, A and B) and induced strong IFN-γ immunity to 
pooled B16 epitopes and to the universal tumor antigen, survivin 
(ref. 42 and Figure 7C). Immunogenicity and antitumor effects of 
the WH-neoepitope-TNE vaccine were Th cell–dependent, as the 
significant tumor suppression observed with WH-TNE was lost if 
CD4+ T cells were depleted during treatment (Figure 7D). These 
data indicate that immunization with WH-neoepitope-TNE stim-
ulates epitope-specific and additional tumor antigen–specific 
immunity, as well as tumor suppression, in a CD4+ T cell–depen-
dent manner. Notably, in the same experiment, all tumor-free 
mice (n = 5) previously treated with WH-neoepitope-TNE were 
protected by subsequent challenge with B16-F10 cells, consistent 
with the induction of a memory response.
Discussion
The Clec9A receptor has been shown to mediate efficient deliv-
ery of antigens derived from necrotic cells to cross-presenting 
DCs. Virally infected cells undergo lysis, thereby exposing the 
Clec9A ligand F-actin. CD8+ DCs take up antigen from dying 
cells via Clec9A, then shuttle F-actin–bound viral proteins into 
the cross-presentation pathway (43). We show here that Cle-
c9A-TNE are a highly efficient and immunogenic system for 
targeted antigen delivery to early endosomes and lysosomes in 
cross-presenting DCs, which can be exploited for generation of 
CTLs and cognate T cell help using protein antigen or pooled 
CD4 and CD8 tumor neoepitope peptides. Accordingly, CTLs 
and high titers of antibody were induced after a single systemic 
administration of OVA-Clec9A-TNE. In contrast, when deliv-
ered as a conjugate, anti-Clec9A–antigen efficiently induced 
specific antibody, but CTLs were not induced without concom-
itant adjuvant or anti-CD40 delivery, commensurate with the 
lack of effect of the conjugate on DCs in vivo (19, 24). In contrast, 
we found that a single administration of antigen–Clec9A-TNE 
activated DCs and induced secretion of IFN-α and specific 
CTLs very efficiently without additional adjuvant in vivo in a 
manner dependent on presentation of CD4 and CD8 cognate 
epitopes, the presence of CD4+ T cells, and expression of CD40, 
MyD88, and IFNAR. Our data are consistent with a model in 
which, after Clec9A-targeted antigen delivery, CD8+ DCs are 
sufficiently activated as a result of pDC type I IFN release and 
antigen-specific CD40-CD40L–mediated CD4+ T cell help to 
induce antigen-specific CTLs without additional adjuvant. Of 
particular interest, CD8+ tumor-infiltrating DCs are also tar-
geted by antigen–Clec9A-TNE, leading to local immune acti-
Tumor growth was significantly inhibited in mice treated either 
with OVA-Clec9A-TNE or with OVA-isotype-TNE, but inhibition 
was greater with OVA-Clec9A-TNE (Figure 4B). The clinical effect 
of OVA-Clec9A-TNE was associated with significantly greater 
infiltration by CD11c+F4/80+CD206– inflammatory DCs and CD4+ 
and CD8+ T cells (Figure 4, C and D, and Supplemental Figure 5). In 
the AT3-OVA model of breast cancer, survival of mice was signifi-
cantly greater after a single administration of OVA-Clec9A-TNE 
than Clec9A-OVA or isotype-OVA conjugates with or without CpG 
adjuvant, or OVA-isotype-TNE (each mouse received 5 μg OVA) 
(Figure 4E). These data indicate that OVA-Clec9A-TNE are taken 
up within tumors, promote an inflammatory tumor environment, 
and prolong the survival of tumor-bearing mice.
Since clinical translation may be hampered by immunogenic-
ity of the Clec9A mAb, we exploited the highly conserved F-actin 
component of the cellular cytoskeleton and a recently described 
WH peptide as specific Clec9A ligands to functionalize nanopar-
ticles targeting either mouse or human cross-presenting DCs (25, 
40). OVA-WH-TNE had a similar size distribution to OVA-Clec9A-
TNE, and maintained stability in serum conditions when stored 
at 4°C for up to 25 days (Supplemental Figure 1C). In vivo uptake 
of F-actin–TNE or WH-TNE by mouse CD8+ DCs and pDCs was 
similar to that of Clec9A-TNE, while control G-actin–TNE were 
not taken up (Figure 4F). Specificity was confirmed by the lack of 
binding of Clec9A-TNE, F-actin–TNE, or WH-TNE to CD8– DCs 
(Supplemental Figure 6). Moreover, mice immunized with F-ac-
tin–TNE, or WH-TNE loaded with OVA, generated antigen-specif-
ic proliferative and cytotoxic responses similar to those of OVA-
Clec9A-TNE (Supplemental Figure 7).
To test the efficacy and immunogenicity of Clec9A-TNE for 
the oncogenic human papillomavirus 16 (HPV16) antigen E6/E7, 
we generated WH-TNE encapsulating recombinant HPV16 E6/E7 
protein and commenced weekly immunization 14 days after s.c. 
implantation of TC1 tumors. While weekly E6/E7 and CpG adju-
vant had no significant impact on tumor growth, WH–E6/E7–TNE 
significantly suppressed TC1 tumor growth (Figure 5A), induced 
strong E6/E7–specific IFN-γ responses in peripheral blood 21 and 
35 days after tumor implantation (Figure 5B), and significant-
ly increased survival of tumor-bearing mice (Figure 5C). After 
tumors became established, we injected DiR-labeled WH–E6/
E7–TNE i.v. to assess biodistribution. Consistent with evidence 
that CD8+ DCs infiltrate tumors (39) and that Clec9A-TNE pro-
mote an inflammatory tumor environment (Figure 4, C and D), 
WH-Clec9A-TNE but not G-actin–TNE localized to tumors as well 
as spleen and liver, while isotype-TNE localized only to spleen and 
liver (Figure 5D). These data indicate that Clec9A-TNE effectively 
target antigen to tumor-infiltrating DCs.
While oncogenic virus expression generates predictable 
immune target antigens suitable for tumor vaccines, neoepitopes 
derived from somatic tumor mutations constitute an alternative 
source of vaccine antigens. In order to exploit peptide neoepitopes 
for vaccination of the murine B16-F10 melanoma model, we first 
developed a system to rank immunogenicity of individual neoepi-
topes using WH-TNE. B16-F10 melanoma cells were implanted 
s.c., and mice were immunized 15 days later with WH-TNE loaded 
with a pool of 18 previously described C57BL/6 B16 neoepitopes 
(41). After 10 days, splenocytes were harvested and restimulated 
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Versatile, personalized, antigen-specific cancer vaccines are a 
long-sought therapeutic strategy in cancer immunotherapy. Cle-
c9A TNE represent such a platform to deliver recombinant tumor 
protein or neoepitope antigens specifically to cross-presenting 
DCs. This platform can fully exploit the neoepitope target reper-
toire for personalized immunotherapeutic approaches.
Methods
Materials and mice. AM1 (molar mass 2,473, 95% purity) (56), WH 
peptide (WPRFHSSVFHTHGGGK), 4T1, and B16-F10 mutated epi-
topes (>95% purity) were synthesized by GL Biochem. Miglyol 812 
was purchased from AXO Industry SA; CellTrace Violet (CTV) from 
Molecular Probes; albumin from chicken egg white (OVA) from Sig-
ma-Aldrich; EndoGrade Ovalbumin (98% purity, <1 EU/mg) from 
Hyglos GmbH; mPEG-NHS (MW 5,000, protein dispersibility index 
<1.08, purity >95%) from Nanocs; and FITC–anti-CD3 (clone 17A2), 
APC/Cy7–anti-CD8 (clone 53.67), PE/Cy7–anti-CD11c (clone N418), 
APC–anti-CD317 (clone 927), PE–anti-CD45.2 (clone 104), PerCP/
Cy5.5–anti–I-A/I-E (clone M5/114.15.2), PerCP/Cy5.5–anti-CD40 
(clone 3/23), PE–anti-CD80 (clone 16-10A1), FITC–anti-CD86 (clone 
GL-1), APC–anti-CD4 (clone RM4-5), PerCP/Cy5.5–anti-CD45 
(clone I3/2.3), PE/Cy7–anti-CD44 (clone IM7), PE–anti-PD 1 (clone 
29F.1A12), APC/Cy7–anti-CD4 (clone RM4-5), APC/Cy7–anti-CD11b 
(clone M1/70), FITC–anti–F4/80 (clone BM8), and APC–anti-CD206 
(clone C068C2) from Biolegend. Anti–mouse LAMP1 (clone 1D4B) 
and anti–mouse EEA1 (clone 14/EEA1) were from BD Bioscienc-
es. LIVE/DEAD Fixable Aqua Dead Cell Stain was from Molecular 
Probes. Cithrol GMO HP was a gift from Croda Europe Ltd. DAMP4 
fused with antibody (mAb-DAMP4) was generated as previously 
described (19, 57). CpG ODN 1668 (catalog tlrl-1668) was purchased 
from InvivoGen, and administered at 5 nmol per dose. Mice were pur-
chased from the Animal Research Centre or bred at the University of 
Queensland, QIMR Berghofer, or James Cook University under specif-
ic pathogen–free conditions.
Preparation of protein antigen in oil dispersion and TNE. Protein 
antigen solution (10 mg/ml) was prepared by dissolving of protein in 
ultrapure water. Cithrol GMO HP solution (1%, wt/vol) was prepared 
by dissolving of Cithrol GMO HP in hexane. Protein and Cithrol GMO 
HP solutions were mixed in a glass vial using a sonicator for 1 min-
ute at 20 W to form a stable water-in-oil emulsion. The emulsion was 
frozen rapidly in dry ice before lyophilization. The antigen–Cithrol 
GMO HP pellet was dissolved in Miglyol 812 to 5 mg/ml and used as 
oil phase. Lyophilized AM1 was dissolved in HEPES containing ZnCl2. 
Miglyol 812 was added to give an oil volume fraction of 2% (vol/vol), 
then homogenized using an ultrasonicator. TNEs were added to 
PEGylated DAMP4 solution, then vigorously stirred (P20-TNE). mAb-
DAMP4 was added to P20-TNE and stirred; then Ab–P20-TNE was 
added to PEGylated DAMP4 and stirred. To prepare F-actin–func-
tionalized TNE (F-actin–TNE), actin was polymerized according to a 
published protocol (40). In brief, rabbit muscle actin was polymerized 
in F-buffer (10 mM Tris-HCl, 50 mM KCl, 2 mM MgCl2, 1 mM ATP 
[pH 7.5]). Polymerized F-actin was added to P20-TNE to a final con-
centration of 50 μg/ml to prepare F-actin–TNE. To prepare WH-TNE, 
WH peptide was first conjugated to DSPE-PEG-NHS. In brief, WH 
peptide was mixed with DSPE-PEG-NHS (1.1 to 1 molar ratio) in 25 
mM HEPES (pH 8.0) for 24 hours at 4°C to allow complete conju-
gation. AM1 (400 μM) was dissolved in 980 μl HEPES (25 mM, pH 
vation, including greater infiltration by inflammatory DCs than 
myeloid suppressor cells and CD4+ and CD8+ T cell infiltration. 
Furthermore, in contrast to passive DC-targeting strategies (7, 
44–46), a single administration of OVA-Clec9A-TNE inhibited 
the growth of and enhanced survival with the relatively immu-
nogenic PyMT-OVA and AT3-OVA breast cancer models. After 
vaccine administration, the burst of IFN-α provoked systemic 
activation of CD8+ and CD8– DCs. IFN-α is a critical predictor of 
immunogenic presentation of antigen and antitumor responses 
after anthracycline chemotherapy and RNA lipoplexes (7, 47). 
Indeed, stimulation of IFN-α secretion emerged as the key dif-
ference between targeting Clec9A as an OVA conjugate or func-
tionalized on TNE. Crosstalk between DCs is essential in vivo 
for efficient CTL induction. While pDCs cross-present weakly, 
if at all, they are known to produce large amounts of IFN-α when 
signaled through TLR9 and CD40, which in turn activates CD8+ 
and CD8– DCs for efficient antigen presentation (48, 49). Based 
on previous observations, we speculate that TLR9 activation is 
triggered as the TNEs reach the early endosome (37, 38).
Our findings indicate that the Clec9A-targeting vaccination 
platform can efficiently exploit the immunogenicity of the unique 
epitopes expressed by oncogenic viruses or generated by somat-
ic mutations, which represent the most potent antigens for cancer 
immunotherapy. Indeed, HPV16 synthetic long peptides used with-
in conventional vaccination approaches induced strong antitumor 
immunity and clinical responses in patients with HPV16-driven car-
cinomas (50–52). More recently, neoantigen vaccines in the form 
of RNA polyepitopes or based on the use of synthetic long peptides 
administered with adjuvant were shown to elicit robust specific T 
cell responses to advanced melanoma, with potential clinical ben-
efits (53, 54). The ability of the TNE vaccination platform to deliver 
tumor antigens directly to cross-presenting Clec9A+ DCs in vivo and 
to induce therapeutically relevant CD8+ and CD4+ T cell respons-
es without the addition of adjuvant has the potential to improve 
the clinical efficacy of personalized cancer immunotherapy. The 
improved potency of this vaccination strategy is supported by the 
observation that the majority of mice vaccinated with WH-neo-
epitope-TNE monotherapy were cured of the highly aggressive 
B16-F10 melanoma and survived for over 50 days. Rational com-
binations with immune checkpoint inhibitors may further increase 
the rate of complete responses and enhance the control of recurrent 
diseases, as shown in preclinical settings and clinical trials (2, 3, 5).
Although neoantigen identification has become feasible and 
affordable by the advances in massively parallel sequencing, algo-
rithms for the prediction of HLA class I and II binding of mutated 
peptides are only partly reliable (55). Our results emphasize the 
need to functionally validate the immunogenicity of candidate 
neoepitopes in order to select the optimal pool of neoantigens to 
be used for effective vaccination. Elimination of epitopes with 
regulatory potential seems to be of particular relevance, as shown 
by the ability of carefully selected B16-F10 neoantigens to induce 
therapeutically relevant immune responses and to eradicate the 
tumor in most of the treated animals. The strength of antitumor 
immune response induced by WH-neoepitope-TNE is also sup-
ported by the observation that tumor-free mice were protected by 
a subsequent challenge with live B16 melanoma cells consistent 
with induction of a memory response.
The Journal of Clinical Investigation R E S E A R C H  A R T I C L E
1 2 jci.org
or soluble OVA (100 μg) (60). After 5 days, CTL targets were prepared. 
Single-cell suspensions of splenocytes from C57BL/6 mice were divid-
ed into 2 parts. One was pulsed with 1 μg/ml OVA257–264 and labeled 
with 5 μM of CTV (CTVhi population). The other was labeled with 0.5 
μM of CTV (CTVlo population). Equal numbers of cells from each were 
pooled, and 107 cells were injected i.v. into recipient mice. Twenty 
hours after injection, the relative proportion of CTVhi to CTVlo cells 
was determined in lymph nodes and spleens by flow cytometry. Per-
centage (%) specific lysis in vivo was calculated by [1 – (r unprimed/ 
r primed)] × 100, where r = % CTVlo/% CTVhi for each mouse. For CTL 
assay using TLR4–/– mice, target cells were labeled with the same con-
centrations of CFSE.
Immunization using OVA-Clec9A-TNE and Clec9A-OVA. Con-
structs of OVA conjugated to anti-Clec9A mAb (Clec9A-OVA) or iso-
type mAb (isotype-OVA) were prepared as previously described (19, 
57). C57BL/6 mice were injected i.v. with 5 μg Clec9A-OVA, OVA-
Clec9A-TNE, isotype-OVA, OVA-isotype-TNE, or PBS in the absence 
of adjuvant. Serum anti-OVA Ig reactivity was measured 1, 2, and 3 
weeks later by ELISA as previously described (19).
ELISA. IFN-α levels were determined in mouse serum or primary 
cell culture media using the VeriKine Mouse IFN Alpha ELISA Kit.
Mouse models. For therapeutic experiments in breast cancer mod-
els, C57BL/6 mice were inoculated orthotopically with 106 AT3-OVA 
or 1.5 × 106 PyMT-mChOVA cells into the mammary gland. For thera-
peutic experiments in the melanoma model, C57BL/6 mice were inoc-
ulated s.c. with 2.5 × 104  B16-F10 melanoma cells into the flank and 
randomly distributed into treatment groups. For therapeutic experi-
ments in the HPV-related cancer model, 105 TC1 cells were inoculated 
s.c. into the flank of C57BL/6 mice. Tumor volumes were measured 
with calipers and calculated using the formula (A × B2)/2 (A as the larg-
est and B as the smallest diameter of the tumor). In therapeutic exper-
iments in the PyMT-mChOVA model, mice received 1 dose of OVA-
Clec9A-TNE or OVA-isotype-TNE (5 μg of OVA per mouse i.v.) either 
8 or 14 days after tumor inoculation. In therapeutic experiments in the 
B16-F10 model, mice received 4 weekly i.v. doses of G-actin–TNE or 
WH-actin-TNE encapsulating E6/E7 protein or a pool of 6 neoepi-
topes, respectively (10 μg of mutated epitopes per mouse), commenc-
ing 2 days after tumor inoculation. Peptides used in B16-F10 studies 
included FRRKAFLHWYTGEAMDEMEFTEAESNM (MUT20), 
STANYNTSHLNNDVWQIFENPVDWKEK (MUT25), PSKPSFQEF-
VDWENVSPELNSTDQPFL (MUT30), DSGSPFPAAVILRDALH-
MARGLKYLHQ (MUT33), CGTAFFINFIAIYHHASRAIPFGTMVA 
(MUT36), EFKHIKAFDRTFANNPGPMVVFATPGM (MUT44), and 
ATFKNWPFL (survivin20–28 universal peptide).
Expression and purification of E6/E7 fusion protein. E6/E7 fusion 
protein was prepared as previously described (61). In brief, E. coli 
BL21(DE3) cells transformed with vector encoding E6/E7 fusion 
protein were used to express the recombinant protein. LB plates 
containing kanamycin sulfate were streaked, and a single colony was 
selected and inoculated into LB media containing kanamycin, and 
expanded. Protein expression was induced with isopropyl-β-thio-
galactopyranoside (IPTG). Cell pellets were stored at –80°C until 
further use. Proteins were purified by Ni-NTA agarose (Qiagen 
Ni-NTA Fast Start Kit). Endotoxin was eliminated using Pierce High 
Capacity Endotoxin Removal Spin Columns. Protein concentration 
was measured by a Thermo Fisher Scientific NanoDrop ND-1000 
spectrophotometer before encapsulation into TNE.
7.0) containing ZnCl2 (800 μM) and DSPE-PEG-WH (8 μM). Twen-
ty microliters Miglyol 812 containing peptides/protein was added to 
yield an oil volume fraction of 2% (vol/vol). The mixture was homog-
enized for four 45-second bursts at 60 W. TNE size was measured by 
a Zetasizer Nano ZS (Malvern Panalytical). Data analysis with DTS 
software used the non-negativity constrained least-squares fitting 
algorithm. Dispersant refractive index and viscosity of the dispersant 
were assumed to be 1.45 and 1.02 centipoise. Each sample had 10 
runs of 10 seconds.
Flow cytometry and confocal microscopy. For TNE in vivo distri-
bution experiments, single-cell suspensions were prepared from 
spleens and stained for I-A/I-E, CD11c, CD317, CD4, and CD8 surface 
markers. Dead cells were excluded using LIVE/DEAD Aqua stain. 
pDCs were gated as I-A/I-E+CD11cintCD317+, CD8+ cDCs as I-A/I-E+ 
CD11chiCD8+, and CD8– cDCs as I-A/I-E+CD11chiCD8–. For FACS 
analysis of tumors, orthotopic PyMT-mChOVA and 4T1.2 mammary 
tumors were excised and single-cell suspensions were made using col-
lagenase D (2 mg/ml; Roche), dispase (2 mg/ml; Gibco), and DNase I 
(0.1 mg/ml; Roche) digestion in RPMI supplemented with 10% FCS. 
After 40 seconds at 37°C in a shaking bath, the cell suspension was 
40-μm-filtered and washed in cold PBS. All cell suspensions were first 
incubated on ice with a 1:1,000 dilution of LIVE/DEAD Aqua for 15 
minutes and then incubated with rat anti–mouse FcγIII/II receptor 
(CD16/CD32) blocking antibodies (4 μg/ml; BD Biosciences) for 15 
minutes on ice. Thereafter cells were stained for CD45, CD11b, F4/80, 
CD11c, CD206, CD4, and CD8 surface markers at 4°C for 40 minutes, 
then washed with PBS containing 2 mM EDTA and 0.5% BSA. For 
intracellular staining, samples were fixed, permeabilized, and stained 
using the FoxP3 transcription factor staining buffer set (eBioscience). 
Samples were acquired on a Beckman Coulter CytoFLEX.
For confocal microscopy, splenic CD11c+ DCs purified from 
C57BL/6 mice were plated on coverslips and incubated with DiI- 
labeled Clec9A-TNE or isotype-TNE for 1 hour at 37°C. After washing 
to remove unbound TNE, cells were incubated in media overnight. 
Cells were fixed with 4% paraformaldehyde and permeabilized with 
100 μg/ml digitonin (Invitrogen) and stained with rat anti–mouse 
LAMP1 or rat anti–mouse EEA1, then Alexa Fluor 488–secondary anti-
body and DAPI (Molecular Probes). Mounted glass coverslips were 
imaged on an Apotome microscope (Carl Zeiss).
In vitro DC stimulation with TNE. Splenic CD11c+ DCs were puri-
fied from C57BL/6, CD40–/–, or TLR9–/– mice (58, 59). CD8+ and CD4+ 
T cells purified from lymph nodes and spleens of OT-I and OT-II trans-
genic mice by negative selection were labeled with CTV. CTV-labeled 
T cells (2 × 104) were cultured with 105 DCs, with or without 2 μl TNE, 
for 16 hours. Cells were washed intensively before staining and flow 
cytometry analysis. Secretion of IFN-α in supernatants was assessed 
by ELISA (VeriKine Mouse IFN Alpha ELISA Kit, PBL Assay Science).
In vivo proliferation assays of transgenic T cells. B6.SJL-Ptprca mice 
were injected i.v. with 3 × 106 CTV-labeled lymph node cells harvest-
ed from OT-I or OT-II transgenic mice. One day later, these recipient 
mice were injected i.v. with 200 μl OVA-Clec9A-TNE, OVA-isotype-
TNE, Clec9A-TNE, or 5 μg soluble OVA protein. Six days later, pro-
liferation of CD3+CD45.2+CD8+ OT-I or CD3+CD45.2+CD4+ OT-II T 
cells was determined by dilution of CTV fluorescence.
In vivo CTL assay. Recipient C57BL/6, Casp1–/–, IFNAR1–/–, or 
MyD88/Trif–/– mice were injected i.v. with 200 μl OVA-Clec9A-TNE or 
OVA-isotype-TNE (both formulated with 5 μg of OVA), Clec9A-TNE, 
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Splenocyte stimulation and CD107/IFN-γ/IL-10 analysis. Spleens 
were removed from tumor-bearing mice and mechanically disrupted 
through a 70-μm cell strainer into a single-cell suspension. Erythro-
cytes were lysed by ACK lysis buffer. Splenocytes (106 cells per 200 μl 
per well) were seeded into a 96-well culture plate and cultured with 
or without individual epitopes (10 μg/ml) at 37°C for 8 hours. BV421–
anti–mouse CD107a (1D4B, Biolegend) and BV421–anti-CD107b 
(ABL-93, BD Biosciences) were added to evaluate degranulation of 
cytotoxic granules. T cells producing IL-10 and IFN-γ were detected 
by intracellular cytokine staining following addition of GolgiPlug (cat-
alog 555029, BD Biosciences) during the last 5 hours of stimulation. 
Staining was performed using FoxP3/Transcription Factor Staining 
Buffer Set (catalog 00-5523-00, eBioscience).
ELISPOT. The IFN-γ release enzyme-linked ImmunoSpot (ELIS-
POT) (41) was carried out using monocytes isolated by a 2-hour plastic 
adherence step from naive syngeneic splenocytes as antigen-presenting 
cells and CD3+ peripheral blood T lymphocytes from tumor-bearing 
mice using the Pan T Cell Isolation Kit II (Miltenyi Biotec) as respond-
ers. Effector and responder cells (25,000 each) were cultured at 37°C for 
48 hours in the presence of anti–IFN-γ–coated (10 μg/ml, clone AN18) 
Multiscreen 96-well plates (Millipore). Cytokine secretion was detected 
with an anti–IFN-γ antibody (1 μg/ml, clone R4-6A2) stimulated with-
out or with 10 μg/ml of peptide. All samples were tested in triplicate.
Statistics. Results are presented as mean with SD of each group. 
Data were statistically analyzed by ordinary 1-way or, where appro-
priate, 2-way ANOVA and Tukey’s multiple-comparisons test, using 
GraphPad Prism software. P values of 0.05 were considered signifi-
cant. Survival analyses used the Mantel-Cox log-rank test.
Study approval. The animal experiments were approved by Animal 
Ethics Committees of the University of Queensland, Brisbane, Austra-
lia, and James Cook University, Townsville, Australia.
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